Free Trial

Vericel (VCEL) Stock Price, News & Analysis

-0.91 (-1.84%)
(As of 07/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
278,190 shs
Average Volume
376,537 shs
Market Capitalization
$2.36 billion
P/E Ratio
Dividend Yield
Price Target

Vericel MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
0.7% Downside
$48.17 Price Target
Short Interest
7.16% of Shares Sold Short
Dividend Strength
News Sentiment
1.44mentions of Vericel in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.95 M Sold Last Quarter
Proj. Earnings Growth
From $0.11 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.18 out of 5 stars

Medical Sector

776th out of 917 stocks

Biological Products, Except Diagnostic Industry

138th out of 152 stocks

VCEL stock logo

About Vericel Stock (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

VCEL Stock Price History

VCEL Stock News Headlines

Vericel Co. (NASDAQ:VCEL) Insider Sells $24,525.00 in Stock
This is the type of environment we pray for…
There is a situation in the market right now that requires your immediate attention. It involves a company that has $9 billion in cash, only $500,000 in debt, and a market cap of around $8 billion. This may not mean much to you right now.
The 3 Highest-Rated Medical Stocks You Can Buy Today
This is the type of environment we pray for…
There is a situation in the market right now that requires your immediate attention. It involves a company that has $9 billion in cash, only $500,000 in debt, and a market cap of around $8 billion. This may not mean much to you right now.
See More Headlines
Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$207.78 million
Cash Flow
$0.02 per share
Book Value
$4.73 per share


Free Float
Market Cap
$2.36 billion

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Dominick C. Colangelo Esq. (Age 60)
    CEO, President & Director
    Comp: $1.54M
  • Mr. Joseph Anthony Mara Jr. (Age 48)
    CFO & Treasurer
    Comp: $750.61k
  • Mr. Michael HalpinMr. Michael Halpin (Age 62)
    Chief Operating Officer
    Comp: $796.91k
  • Mr. Sean C. FlynnMr. Sean C. Flynn (Age 50)
    Chief Legal Officer
    Comp: $657.01k
  • Dr. Jonathan M. Hopper FRCSEd. (Age 62)
    M.B. Ch.B., Chief Medical Officer
    Comp: $672.16k
  • Mr. Jonathan D. Siegal
    Principal Accounting Officer, VP & Corporate Controller
  • Mr. Eric Burns
    Vice President of Finance & Investor Relations
  • Mr. Patrick J. Fowler
    Senior Vice President of Corporate Development & Strategy
  • Mr. Patrick Helfrich
    Vice President of Marketing & Commercial Strategy
  • Mr. Mike Gilligan
    Senior Vice President of Sales

VCEL Stock Analysis - Frequently Asked Questions

How have VCEL shares performed this year?

Vericel's stock was trading at $35.61 on January 1st, 2024. Since then, VCEL stock has increased by 36.2% and is now trading at $48.50.
View the best growth stocks for 2024 here

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) announced its earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. The company's revenue for the quarter was up 25.0% compared to the same quarter last year.

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are Vericel's major shareholders?

Top institutional shareholders of Vericel include Linden Thomas Advisory Services LLC (0.09%), SG Americas Securities LLC (0.02%), Juncture Wealth Strategies LLC (0.02%) and Contravisory Investment Management Inc. (0.01%). Insiders that own company stock include Dominick Colangelo, Robert L Md Zerbe, Steven C Gilman, Jonathan Siegal, Michael Halpin, Sean C Flynn and Jonathan Mark Hopper.
View institutional ownership trends

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

This page (NASDAQ:VCEL) was last updated on 7/13/2024 by Staff

From Our Partners